Report cover image

Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Jun 02, 2022
Length 52 Pages
SKU # GBDT17290805

Description

Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Aicardi-Goutieres Syndrome therapeutics.

Synopsis
  • There will be more than 4,000 prevalent cases of AGS each in 2022 across the 16 countries covered in GlobalData’s epidemiology forecast.
  • No FDA-approved marketed drugs are available for AGS, only symptomatic treatment is indicated for disease management.
  • The drug currently in late-stage clinical development targets tyrosine kinase.
  • Non-commercial sponsors dominate clinical trial development in AGS.
  • No deals involving companies developing AGS assets were seen over the past 10 years.
  • No regulator filing or commercial launch is expected for AGS in the next 18 months.
Scope

GlobalData’s Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Sponsors and Geography
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Aicardi-Goutieres Syndrome market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Aicardi-Goutieres Syndrome market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

52 Pages
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Total Prevalent Cases of AGS in 2022 and 2027
    • Treatment Guidelines
    • Marketed Drugs - Leading Marketed Drugs in AGS
    • Pipeline Drugs Overview - Pipeline and Pre-clinical Drugs in AGS
    • Pipeline Drugs Overview - Inactive/Withdrawn/Discontinued Drugs in AGS
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Genetic Disorders
    • Clinical Trials in AGS - Historical Overview
    • Clinical Trials in AGS - Overview by Phase
    • Clinical Trials in AGS - Overview by Status
    • Clinical Trials in AGS - Geographic Overview
    • Clinical Trials in AGS - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in AGS - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in AGS - Enrollment Data
    • Clinical Trials in AGS - Overview of Sites by Geography
    • Clinical Trials in AGS - Top 20 Countries for Trial Sites
    • Clinical Trials in AGS - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for AGS
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in AGS
    • Commercial Assessment - Key Market Players in AGS
    • Future Market Catalysts - Upcoming Market Catalysts in AGS
    • Methodology
    • Methodology - PTSR and LoA Analysis
    • About the Authors
    • Contact Us - A Global Network of Offices

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us